ArticleInfection2025
Head-to-head: meropenem/vaborbactam versus ceftazidime/avibactam in ICUs patients with KPC-producing K. pneumoniae infections- results from a retrospective multicentre study.
Article in Infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness and safety of meropenem-vaborbactam versus ceftazidime-avibactam in multidrug-resistant Gram-negative infections: a systematic review and meta-analysis with trial sequential analysis.Antimicrobial agents and chemotherapy · 2026Pooled it
- Ceftazidime-avibactam as monotherapy or in combination for targeted treatment of KPC-producing Klebsiella pneumoniae infections in ICUs: a comparative analysis through counterfactual framework and desirability of outcome ranking.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Observational
- Challenges and opportunities in the management of severe pneumonia. Key concepts from the Seventh Annual Meeting of Spanish Experts 2025.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections.Antimicrobial agents and chemotherapy · 2026Article
- Aminoglycosides enhance meropenem/vaborbactam activity against KPC-producingAntimicrobial agents and chemotherapy · 2026Article
- Real-World Evidence and Multidrug Resistant Infections: How Can We Leverage RWE to Improve Patient Outcome with the Novel Beta-Lactam and Beta-Lactam/Beta-Lactamase Inhibitor Combinations.Infection and drug resistance · 2026Review
- Synergistic Interactions Between Natural Phenolic Compounds and Antibiotics Against Multidrug-ResistantMicroorganisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMeropenem/vaborbactam (M/V) and ceftazidime/avibactam (C/A) are considered key agents in treating KPC-producing Klebsiella pneumoniae (Kp) infections. We compared these two drugs in ICUs patients with BSI and/or pneumoniae due to KPC- Kp.
methodsThis retrospective multicentre study analysed ICU patients with bloodstream infections (BSI) and/or pneumonia caused by KPC-Kp across five Italian ICUs from January 2021 to December 2023. Propensity-score matching (PSM) was applied to mitigate the impact of confounding factors. The primary outcome was 30-day all-cause mortality. Secondary outcomes included early clinical improvement at 72 h, computing the odds ratio (OR) as effect size, and infection-related events. Subgroup analyses were performed based on relevant prognostic factors.
resultsThe study included 177 patients, with 88 subjects paired after-matching (52 treated with C/A and 36 with M/V). As for primary outcome, after PSM, no statistically significant differences in 30-day mortality were observed between the two groups: in the Kaplan-Meier survival log-rank test was p = 0.38, and PSM-adjusted HR of M/V on mortality was 0.65 (95% CI 0.55–1.68). As for secondary outcomes, M/V significantly improved early clinical response post-PSM (OR: 2.19, 95% CI: 1.35–3.55).
conclusionsM/V showed no statistically significant difference in 30-day mortality compared to C/A but demonstrated significantly improved in early clinical response for patients with KPC-Kp. These findings were consistent between unmatched and matched patients. Further prospective studies are warranted to validate these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.